ABSTRACT
Native human interleukin-2 (IL-2) comprises a group of glycoproteins of MW 13,000-17,500. Recombinant human IL-2 (rhIL-2) (Cetus) is derived from E. coli and is not glycosylated. We have evaluated several processes for manufacturing rhIL-2, based on different chaotropic agents for solubilization of insoluble protein pastes. Formulation work carried out with material purified by one of these processes is reported here. Our studies have indicated that the presence of a stabilizer in the form of an amorphous excipient, such as amino acids, a non-ionic surfactant (polysorbate 80), hydroxypropyl-beta-cyclodextrin or human serum albumin was essential for preservation of rhIL-2 during lyophilization. Each of these formulations exhibited its own unique problems. We have overcome these problems through a systematic formulation development program and have been successful in developing several lyophilized formulations of rhIL-2 with optimum properties and performance.
Subject(s)
Freeze Drying/methods , Interleukin-2/isolation & purification , beta-Cyclodextrins , 2-Hydroxypropyl-beta-cyclodextrin , Amino Acids/chemistry , Chemistry, Pharmaceutical , Cyclodextrins , Drug Stability , Escherichia coli , Glycosylation , Humans , Interleukin-2/chemistry , Polysorbates , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Serum AlbuminABSTRACT
The acute inflammatory response requires that circulating leukocytes bind to and penetrate the vascular wall to access the site of injury. Several receptors have been implicated in this interaction, including a family of putative carbohydrate-binding proteins. We report here the identification of an endogenous carbohydrate ligand for one of these receptors, endothelial-leukocyte adhesion molecule 1 (ELAM-1). Radiolabeled COS cells transfected with a plasmid containing the cDNA for ELAM-1 were used as probes to screen glycolipids extracted from human leukocytes. COS cells transfected with this plasmid adhered to a subset of sialylated glycolipids resolved on TLC plates or adsorbed on polyvinyl chloride microtiter wells. Adhesion to these glycolipids required calcium but was not inhibited by heparin, chondroitin sulfate, keratan sulfate, or yeast phosphomannan. Monosaccharide composition, linkage analysis, and fast atom bombardment mass spectrometry of the glycolipids indicate that the ligands for ELAM-1 are terminally sialylated lactosylceramides with a variable number of N-acetyllactosamine repeats and at least one fucosylated N-acetylglucosamine residue.
Subject(s)
Cell Adhesion Molecules/metabolism , Cell Adhesion , Animals , Base Sequence , Carbohydrate Conformation , Carbohydrate Sequence , Carbohydrates , Cell Adhesion Molecules/genetics , Cell Line , Cloning, Molecular , E-Selectin , Glycolipids/metabolism , Humans , Ligands , Mass Spectrometry , Membrane Glycoproteins/metabolism , Molecular Sequence Data , Neutrophils/physiology , Oligonucleotide Probes , Polymerase Chain Reaction , TransfectionABSTRACT
We have examined the effects of a variety of chemical modifications to recombinant human interleukin-2 (rIL-2) on its pharmacokinetic behavior in rats. Unmodified rIL-2 is cleared from plasma with half-lives of 3 and 44 min for the alpha and beta phases. Modification of rIL-2 with monomethoxy polyethylene glycol or polyoxyethylated glycerol increased the half-lives as much as 20-fold, although the volume of distribution remained unchanged at 88 +/- 13 ml/kg. The clearance rates correlated with the effective molecular size of the modified protein determined by size exclusion chromatography. Clearance decreased rapidly as the effective molecular size increased from 19.5 to 70 kDa, whereas above 70 kDa the clearance decreased more slowly. This abrupt change at 70 kDa may be related to the permeability threshold of the kidney glomerular membrane which retains proteins larger than albumin in the plasma. Using the relationship between clearance and effective molecular size, the clearance rates of mixtures of modified rIL-2 could be predicted based on their average effective molecular size. Since the effectiveness of rIL-2 therapy is likely to be related to its pharmacokinetic behavior, the ability to design a molecule with a predictable time course in plasma provides a means to study this relationship.
Subject(s)
Interleukin-2/pharmacokinetics , Recombinant Proteins/pharmacokinetics , Animals , Chromatography, High Pressure Liquid , Escherichia coli/genetics , Glycerides/pharmacology , Half-Life , Interleukin-2/genetics , Isoelectric Focusing , Male , Metabolic Clearance Rate , Molecular Weight , Polyethylene Glycols/pharmacology , Rats , Structure-Activity RelationshipABSTRACT
Human recombinant interleukin-2 (IL-2) and related species have been characterized by chemical modifications, tryptic digestion, and cyanogen bromide digestion. The oxidation states of the cysteines and methionines in several IL-2 muteins have been determined. Reversed-phase high-performance liquid chromatography allowed us to distinguish the modifications in these muteins and to correlate retention behavior with their structure.
